Filing Details
- Accession Number:
- 0001209191-17-057319
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-10-18 17:35:05
- Reporting Period:
- 2017-10-16
- Accepted Time:
- 2017-10-18 17:35:05
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1610876 | Jeffrey Chodakewitz | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp Gmda, Cmo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-10-16 | 1,718 | $96.87 | 116,142 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-10-16 | 300 | $153.42 | 115,842 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-10-16 | 818 | $154.76 | 115,024 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-10-16 | 300 | $155.92 | 114,724 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-10-16 | 300 | $157.38 | 114,424 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2017-10-16 | 1,718 | $0.00 | 1,718 | $96.87 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
5,157 | 2024-07-14 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $153.42 (range $153.11 to $153.58).
- Open market sales reported on this line occurred at a weighted average price of $154.76 (range $154.50 to $155.15).
- The option vests in 16 quarterly installments from 7/15/2014.